Wegovy (semaglutide injection) is now approved to reduce the risk of non-fatal myocardial infarction in adults with established cardiovascular disease and BMI equal to or greater than 27 kg/m2. It is the first Health Canada approved treatment to support both chronic weight management and to reduce the risk of non-fatal MI.
Novo Nordisk Says Health Canada Approves Wegovy (Semaglutide Injection) To Reduce Risk Of Non-Fatal Myocardial Infarction
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated